Impact of Adipose Tissue Repartition on the Time Course of Vascular Dysfunction - the NUMEVOX Cohort

This study is currently recruiting participants.
Verified October 2009 by University Hospital, Angers
Sponsor:
Information provided by:
University Hospital, Angers
ClinicalTrials.gov Identifier:
NCT00997165
First received: October 16, 2009
Last updated: NA
Last verified: October 2009
History: No changes posted

October 16, 2009
October 16, 2009
March 2008
March 2014   (final data collection date for primary outcome measure)
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Impact of Adipose Tissue Repartition on the Time Course of Vascular Dysfunction - the NUMEVOX Cohort
Impact of Adipose Tissue Repartition on the Time Course of Vascular Dysfunction - the NUMEVOX Cohort

The NUMEVOX cohort is intended to follow-up the macro and microvascular dysfunction in relation to adipose tissue repartition in patients with metabolic syndrome associated to liver steatosis, sleep apnea. Duration of the follow-up is 3 years for each patient entering the cohort.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

serum and DNA

Non-Probability Sample

Any patient suspected of metabolic syndrome with or without sleep apnea or liver steatosis.

Informed consent with signature.

  • Metabolic Diseases
  • Sleep Apnea
  • Atherosclerosis
Not Provided
  • Metabolic syndrome (MS)
    Patients suspected of metabolic syndrome without sleep apnea or liver steatosis
  • MS with sleep apnea
    Metabolic syndrome with sleep apnea
  • MS with Liver steatosis
    Metabolic syndrome with liver steatosis
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
500
March 2017
March 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • informed consent
  • age > 18 years old
  • suspected of metabolic syndrome
  • affiliated to french social health care

Exclusion Criteria:

  • age < 18 years old
  • pregnancy
  • no informed consent
  • not eligible for the study (no MS, cancer)
Both
18 Years to 80 Years
No
Contact: PIERRE HENRI DUCLUZEAU, MD PhD 33(0)663384160 phducluzeau@chu-angers.fr
Contact: GEORGES LEFTHERIOTIS, MD-PHD 33(2)41-35-44-56 geleftheriotis@chu-angers.fr
France
 
NCT00997165
CHU-Promoteur 08-01
No
Pierre Henri Ducluzeau/MD-PhD, UH Angers
University Hospital, Angers
Not Provided
Study Director: pierre henri Ducluzeau, MD PhD UH Angers
University Hospital, Angers
October 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP